Corvus Pharmaceuticals, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Corvus completed a $189.4M financing in January 2026 (net proceeds), bringing cash to $215.2M as of June 30, 2026, versus $56.8M at year-end 2025. The company has ~22 months of runway into Q2 2028. Soquelitinib Phase 3 PTCL and Phase 2 atopic dermatitis trials are enrolling on schedule; Corvus invested $5M in Angel Pharmaceuticals' $13.5M round to fund their atopic dermatitis Phase 1b/2 and asthma Phase 2 trials in China. Q2 2026 net loss was $18M ($17.96M per share loss of $0.19) versus $8M in Q2 2025, driven by higher R&D spend ($16M vs $7.9M).
Why this rating
Major capital raise (3.8× company market cap) extended runway materially and funds multiple clinical programs. Meaningful for a clinical-stage biotech, but not transformational without clinical success.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.